These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31027751)

  • 1. Response of BRAF
    Yamamoto G; Sakakibara-Konishi J; Ikari T; Kitai H; Mizugaki H; Asahina H; Kikuchi E; Shinagawa N
    J Thorac Oncol; 2019 May; 14(5):e97-e99. PubMed ID: 31027751
    [No Abstract]   [Full Text] [Related]  

  • 2. An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.
    Abravanel DL; Nishino M; Sholl LM; Ambrogio C; Awad MM
    J Thorac Oncol; 2018 Aug; 13(8):e131-e133. PubMed ID: 29631033
    [No Abstract]   [Full Text] [Related]  

  • 3. Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer.
    Pervere LM; Rakshit S; Schrock AB; Miller VA; Ali SM; Velcheti V
    Clin Lung Cancer; 2017 May; 18(3):e211-e213. PubMed ID: 28024926
    [No Abstract]   [Full Text] [Related]  

  • 4. Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
    Rogiers A; Thomas D; Vander Borght S; van den Oord JJ; Bechter O; Dewaele M; Rambow F; Marine JC; Wolter P
    Br J Dermatol; 2019 Feb; 180(2):421-422. PubMed ID: 30248172
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.
    Reyes R; Mayo-de-Las-Casas C; Teixidó C; Cabrera C; Marín E; Vollmer I; Jares P; Garzón M; Molina-Vila MÁ; Reguart N
    Clin Lung Cancer; 2019 May; 20(3):e219-e223. PubMed ID: 30926357
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
    Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
    Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabrafenib plus trametinib in patients with previously untreated BRAF
    Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
    Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation.
    Dotsu Y; Fukuda M; Honda N; Gyotoku H; Kohno Y; Suyama T; Umeyama Y; Taniguchi H; Takemoto S; Yamaguchi H; Miyazaki T; Sakamoto N; Obase Y; Ikeda H; Ashizawa K; Mukae H
    Thorac Cancer; 2021 Jan; 12(2):272-276. PubMed ID: 33215864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple Therapy Improves Colorectal Cancer Response.
    Cancer Discov; 2016 Dec; 6(12):OF6. PubMed ID: 27770002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeated complete response with long-term control of BRAF-mutant melanoma by multiple rechallenges with dabrafenib plus trametinib.
    Sasaki K; Nakamura Y; Baba N; Teramoto Y; Yamamoto A
    Eur J Cancer; 2020 Nov; 139():37-40. PubMed ID: 32957012
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAF
    Chic N; Mezquita L; Aldea M; Chebib R; Caramella C; Planchard D; Besse B
    Clin Lung Cancer; 2021 Jan; 22(1):e54-e56. PubMed ID: 32896487
    [No Abstract]   [Full Text] [Related]  

  • 13. Adverse Event Management in Patients with
    Chalmers A; Cannon L; Akerley W
    Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dabrafénib and tramétinib in BRAF V600E mutated pediatric gliomas].
    Giorgis O; Doz F
    Bull Cancer; 2024 May; 111(5):429-430. PubMed ID: 38471994
    [No Abstract]   [Full Text] [Related]  

  • 15. A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
    Marchand A; Tallet A; Collin C; Cormier B; Venel Y; Miquelestorena-Standley E; Machet L
    Br J Dermatol; 2018 Aug; 179(2):528-529. PubMed ID: 29494756
    [No Abstract]   [Full Text] [Related]  

  • 16. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.
    Khunger A; Khunger M; Velcheti V
    Ther Adv Respir Dis; 2018; 12():1753466618767611. PubMed ID: 29595366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
    Dummer R; Hauschild A; Santinami M; Atkinson V; Mandalà M; Kirkwood JM; Chiarion Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Gasal E; Tan M; Long GV; Schadendorf D
    N Engl J Med; 2020 Sep; 383(12):1139-1148. PubMed ID: 32877599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary CNS Metastatic BRAF-mutated Lung Adenocarcinoma With Complete Intracranial Response to BRAF/MEK Inhibition.
    Tsakonas G; Grozman V; Ekman S
    Clin Lung Cancer; 2020 Nov; 21(6):e544-e546. PubMed ID: 32522509
    [No Abstract]   [Full Text] [Related]  

  • 19. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
    Dhillon S
    Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabrafenib Effective in Pediatric Glioma.
    Cancer Discov; 2017 Jan; 7(1):OF5. PubMed ID: 28062673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.